4//SEC Filing
O'Loughlin Steve 4
Accession 0001213900-22-036877
CIK 0001388320other
Filed
Jun 30, 8:00 PM ET
Accepted
Jul 1, 7:19 PM ET
Size
5.5 KB
Accession
0001213900-22-036877
Insider Transaction Report
Form 4
O'Loughlin Steve
Chief Financial Officer
Transactions
- Award
Stock Option (Right to Buy)
2022-07-01+256,438→ 256,348 totalExercise: $4.96Exp: 2032-07-01→ Common Stock (256,438 underlying)
Footnotes (2)
- [F1]This price represents the closing price of the Company's common stock on July 1, 2022, the date of the grant.
- [F2]Pursuant to the terms of the Company's 2019 Stock Plan, 2% of the options will vest each month from July 1, 2022 until fully vested.
Documents
Issuer
Actinium Pharmaceuticals, Inc.
CIK 0001388320
Entity typeother
Related Parties
1- filerCIK 0001615840
Filing Metadata
- Form type
- 4
- Filed
- Jun 30, 8:00 PM ET
- Accepted
- Jul 1, 7:19 PM ET
- Size
- 5.5 KB